Top Markets
#1 Black Phoenix Black Phoenix +355.39%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.09%
#4 Akedo Akedo +46.58%
#5 Acurast Acurast +34.72%
#6 BasedHype BasedHype +25.74%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.14%
#8 Avantis Avantis +22.16%
#9 Cryptopia Cryptopia +21.54%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.89%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Rang in Aktien #40870
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Aktienkurs
$0.02765
Zuletzt synchronisiert: 2024-12-23
Marktkapitalisierung
$69.04K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Histogen Inc. (HSTO)

Kategorie

Healthcare
P/S-Verhältnis für Histogen Inc. (HSTO)
P/S-Verhältnis zum August 2026 TTM: 0.02
Laut den neuesten Finanzberichten und dem Aktienkurs von Histogen Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0.02. Am Ende des Jahres 2021 lag das P/S-Verhältnis bei 1.38.
P/S-Verlauf für Histogen Inc. von 2011 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 0.02 -67.57%
2022 0.07 -94.87%
2021 1.38 313.79%
2020 0.33 -19.32%
2019 0.41 163.81%
2018 0.16 -58.10%
2017 0.37 -97.50%
2016 14.94 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 43,427.75%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 45,287.67%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 21,835.24%
BE